Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Jun 21, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new testing method called ChromoSeq to see if it can help doctors better understand and treat patients with myelodysplastic syndromes (MDS), a group of diseases that affect how blood cells are produced. The study will collect information from patients and their doctors to find out if adding ChromoSeq to standard tests can improve patient care.

To be eligible for this trial, patients need to be at least 18 years old and have either a confirmed diagnosis of MDS or a strong suspicion of it, and they should not have received any treatments that change the disease before joining the study. Participants will be seen in an outpatient setting, meaning they won't need to stay in the hospital. They will also be asked to provide consent to participate in the study, which will help researchers learn more about how ChromoSeq can be used in managing MDS. This trial is currently recruiting participants, and it's being conducted at Washington University School of Medicine.

Gender

ALL

Eligibility criteria

• Inclusion Criteria Patient:
• • Diagnosis of MDS, or a clinical suspicion for a new diagnosis of MDS, for whom routine diagnostic testing is requested or planned to be requested.
• • Seen in the outpatient setting.
• • Not been previously treated with disease-modifying therapy (such as lenalidomide or hypomethylating agents).
• • Note: Patients who have received transfusional support, erythropoietin-stimulating agents, growth factor support, or luspatercept are eligible.
• • At least 18 years of age.
• • -Able to understand and willing to sign an IRB approved written informed consent document.
• Inclusion Criteria Physician:
• • Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.
• • Able and willing to complete standardized questionnaires about stakeholder perceptions of ChromoSeq during the ChromoSeq implementation process. (Written documentation of informed consent is not required.)
• Exclusion Criteria Patient:
• • -Younger than 18 years of age
• • Exclusion Criteria Physician
• • -Does not treat patients at Washington University School of Medicine